Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0113 vaccine in CMV-seronegative kidney transplant recipients with CMV-seropositive donors
2013-000464-29Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Feb 2014
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cytomegalovirus disease (CMV) comparing ASP0113 with Placebo (2 arms). Primary endpoint: Incidence of CMV viremia through one year after first study drug injection. Started Feb 2014; status: completed.
02
Drugs
ASP0113
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2013-000464-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000464-29.